| 2026-08-18 | Press release | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-08-05 | Press release | Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference |
| 2026-08-03 | Press release | Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates |
| 2026-08-03 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-03 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-03 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-27 | Press release | Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates |
| 2026-07-16 | Press release | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-07-13 | Press release | Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer |
| 2026-06-30 | Press release | Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome |
| 2026-06-30 | 8-K | Form 8-K, Item 7.01 |
| 2026-06-16 | Press release | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-06-04 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-28 | Press release | Stoke Therapeutics to Present at Upcoming Investor Conferences in June |
| 2026-05-18 | Press release | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-05-07 | Press release | Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-30 | Press release | Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates |
| 2026-04-22 | Proxy | Definitive proxy statement |
| 2026-04-07 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-27 | 8-K | Form 8-K, Item 4.01 |
| 2026-03-16 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-03 | 8-K | Form 8-K, Item 5.02 |
| 2026-01-26 | 8-K | Form 8-K, Item 1.01 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-05 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-04 | Press release | Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-30 | Press release | Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates |
| 2025-10-06 | 8-K | Form 8-K, Item 5.02 |
| 2025-09-18 | 8-K | Form 8-K/A, Item 5.07 |
| 2025-08-18 | Press release | Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2025-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-08-11 | Press release | Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome |
| 2025-08-11 | 8-K | Form 8-K, Item 7.01 |
| 2025-07-10 | 8-K | Form 8-K, Item 7.01 |